Allergan's Freedom From Expression Suit Challenges Gov't REMS, Off-Label Powers
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm wants to go beyond the REMS requirements and offer treatment guidance, not just risk information, about the use of Botox for spasticity, an unapproved condition.
You may also be interested in...
Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ
Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.
Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ
Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.
Waxman Staffer Ann Witt Rejoining FDA
The former DDAMC head will bring wide knowledge of promotion and follow-on biologic issues to policy discussions.